Keros Therapeutics Inc Net Income per Employee (KROS), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Keros Therapeutics Inc   (NASDAQ: KROS)
 

Keros Therapeutics Inc Net Income per Employee

KROS's Quarterly Results, Trends, Rankings, Statistics
Keros Therapeutics Inc recorded a cumulative net loss of $-85 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 192 other companies achieving higher income per employee. While Keros Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 148 to 3603.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KROS Net Income per Employee (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,091,603 1,115,564 826,269 240,679 54,000
KROS's Total Ranking # 3603 # 148 # 315 # 1099 #
Seq. Net Income Change - - - - -

KROS Company Profile >> Back to KROS Efficiency Comparisons >> Compare KROS Net Income per Employee to its Competitors

KROS Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 193
Healthcare Sector # 538
Overall Market # 3603

Net Income per Employee Statistics
High Average Low
$ 1,400,949 $ -955,456 $ -2,401,962
(Dec 31 2025)   (Dec 31 2024)




  News about Keros Therapeutics Inc Income per employee

Keros Therapeutics Aims High with Proposed Public Offering, Igniting Excitement in Transformative Biopharmaceutical Frontier

Keros Therapeutics Aims to Harness Transformative Potential of TGF-Beta Proteins with New Public Offering
LEXINGTON, Mass., Jan. 03, 2024 - Keros Therapeutics, a pioneering clinical-stage biopharmaceutical company dedicated to addressing disorders associated with dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins, has unveiled its plans for a proposed underwritten public offering. With the aim of developing and commercializing innovative therapeutics, Keros intends to raise $120.0 million through the sale of common stock.
This strategic move in the form of a public offering demonstrates Keros Therapeutics steadfast commitment to advancing treatment options for patients suffering from a myriad of disorders linked to TGF-β protein signaling dysfunction. By pooling resources through the offering, Keros will be better equipped to drive vital research and development efforts, ensuring the accelerated advancement of novel therapeutics.




Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2026Number of Employees Mar 31 2026


Date modified: 2026-08-29T17:41:26+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.